Description
TRIKAFTA is a combination of ivacaftor, a CFTR potentiator, tezacaftor, and elexacaftor indicated for the treatment of cystic fibrosis (CF)
Elexacaftor/tezacaftor/ivacaftor, sold under the brand name Trikafta, is a fixed-dose combination medication used in those that have cystic fibrosis with a f508del mutation. It is made up of a combination of elexacaftor, tezacaftor, and ivacaftor. It was approved for medical use in the United States in 2019. In June 2020, the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) recommended the approval of elexacaftor/tezacaftor/ivacaftor (Kaftrio) for the treatment of cystic fibrosis. It was approved for medical use in the European Union in August 2020.
How can 1 go about obtaining TRIKAFTA ?
If TRIKAFTA (elexacaftor, tezacaftor and ivacaftor tablets) are not yet approved or available in your area, you may request its price in India under a specific brand name through IPN. For assistance and guidance, you can contact us by providing complete details. Our pharmaceutical expert will help you find a suitable and practical solution to your query. To receive comprehensive support, please call us at +91 9891 296 838 (Mr. Tarun) / +91 9811 747 774 (Mr. Neeraj).
Note:
We are the facilitator, group of highly qualified healthcare professionals, provide solutions on how to get access of anti cancer medicines not available in India. On the basis of permission in Form 12B (Import permit) from From Ministry of Health, Government of India, IPN, New Delhi procure drugs on behalf of patient.
NEWS / UPDATES
- For TRIKAFTA (elexacaftor, tezacaftor and ivacaftor tablets) Indications And Usage, Dosage And Administration, Dosage Forms And Strengths and Drug Interactions For More Details
- Health Canada Giving Priority Review to Trikafta For More Details
- Top 10 Cystic Fibrosis Stories of 2020 For More Details